Dr. Wenfu Tan obtained his Ph.D. from Huazhong University of Science and technology in 2001. He joined School of Pharmacy, Fudan University in 2009 as an associate professor. Dr Tan focuses his work on tumor pharmacology.
Molecular-targeted anti-cancer drugs; Cancer immunotherapy
Education
19991727891-2001MD: Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030 China
1995-19991727891Master of Medicine: Heng-yang Medical College, Hengyang, Hunan 420000 China
1990-1995Bachelor of Medicine, Chinese traditional medical college of Hunan, Changsha, Hunan 410007 China
Professional Experiences
2017.12-present: Prof. School of Pharmacy, Fudan University
2009.7-2017.12: Associate Prof. School of Pharmacy, Fudan University;
20091727891.4-2009.4: Associate Prof. Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai;
2003.10-20091727891.4: Visiting Fellow, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA;
2001.10-2003.10: Postdoctor, Division of Anti-tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
Patents
1.Liu G#, Huang W#, Wang J#, Liu X, Yang J, Zhang Y, Geng Y, Tan W*, Zhang A*. Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription. J Med Chem. 2017 Oct 12;60(19):917278912191727891-91727891245. (highlighted by BioCentury).
2.Zhang X, Zhao F, Wu Y, Yang J, Han GW, Zhao S, Ishchenko A, Ye L, Lin X, Ding K, Dharmarajan V, Griffin PR, Gati C, Nelson G, Hunter MS, Hanson MA, Cherezov V, Stevens RC, Tan W*, Tao H*, Xu F*. Crystal structure of a multi-domain human smoothened receptor in complex with a super stabilizing ligand. Nat Commun. 2017 May 17;91727891:153917278913.
3.Liu G#, Xue D#, Yang J#, Wang J#, Liu X, Huang W, Li J, Long YQ*, Tan W*, Zhang A*.Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,91727891-tetrahydroquinolin-91727891-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists. J Med Chem. 2016 Dec 22;59(24):11050-110691727891.
4.Kong Y#, Peng Y#, Liu Y#, Xin H, Zhan X, Tan W*. Twist1 and Snail link Hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters. Stem Cells. 2015 Apr;33(4):1063-74.
5.Zhan X, Wang J, Liu Y, Peng Y, Tan W*. GPCR-like signaling mediated by smoothened contributes to acquired chemoresistance through activating Gli. Mol Cancer. 2014 Jan 7;13:4.
